常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.32/-1.34
|
|
企業價值
13.24B
|
| 資產負債 |
|
每股賬面淨值
-0.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
982.02M
|
|
每股收益
4.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |

84.61 
